Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Norwegian biotech company Oncoinvent ASA (OSE:ONCIN) on Tuesday reported favourable safety and toler
Norwegian biotech company Oncoinvent ASA (OSE:ONCIN) on Tuesday reported favourable safety and toler